Company Overview and News
Shares of Kroger (NYSE:KR) fell 10% in early trade Sept. 13 after it released earnings that beat estimates on the bottom line but came up short on the top. Fortunately for investors, most of the loss had been regained within one week.
KR COST M WMT
Since mid-April, Costco Wholesale Corporation (NASDAQ:COST) stock has had quite a run. COST stock was somewhat choppy in 2017, but 2018 has been a different story. Costco stock has gained 25% so far this year, and nearly all of the gains have come over the last five months.
WFC WFCNP COST WMT TGT V KR AMZN
The Dow Jones Industrial Average finally pushed above its January record high on Thursday, ending a year-long consolidation range that was spurred by worries over higher interest rates, Federal Reserve policy tightening and the fallout from President Trump’s trade war.
WFCNP PG CAT AXP IBM WFC COST UTX JNJ BA
Visa, Mastercard, and a number of US banks agreed to pay $6.2 billion to settle a long-running lawsuit brought by merchants over the fees they pay when they accept card payments.
NEW YORK (Sept 18): Visa Inc, Mastercard Inc, and a number of US banks on Tuesday agreed to pay US$6.2 billion to settle a long-running lawsuit brought by merchants over the fees they pay when they accept card payments.
V COST MA
Costco Wholesale Corporation (COST - Free Report) has surged 27.8% in the past six months compared with the industry’s growth of 23.6%. This Zacks Rank #3 (Hold) company has also comfortably outperformed the Retail-Wholesale sector that advanced 11% during the aforementioned period. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. The company continues to be one of the dominant warehouse retailers based on the breadth and quality of merchandise offered.
TGT COST ROST WMT
Stocks were indicated to open marginally lower after news that President Trump is set to enact more tariffs against China. U.S. equity indexes remain very close to all-time highs, while most international markets are not close to theirs. One issue that must be considered is that investors have seen less upside from buying on market pullbacks than in prior years. Investors also need to be considering how they want to have their investments positioned for the rest of 2018.
ATHTF COST AXP ANTM V TWTR KHC TRI CI PLAY ARMK ADS BBBY ANTX
2018-09-14 seekingalpha - 1
With a low unemployment rate, an inflation rate drifting toward the Federal Reserve's target, and increased spending, current interest rates don't adequately match the strength of the economy.
BAC BAC COST
Stocks were indicated to open marginally higher on Friday, but not so much that the direction of this day looked set. U.S. equity indexes remain near all-time highs at a time that most international markets are not close to their highs. One issue that stands out to U.S. investors is that they have seen less upside from buying on market pullbacks than in prior years. Investors also need to consider how they want to have their investments positioned for the rest of 2018.
WFCNP YELP ADBE WMT WFC GLW ANGI COST GRUB DHI DNKN TRI
Target (NYSE:TGT) announced Thursday that it is set to hire 20% more seasonal workers during the upcoming holiday shopping period, with a sizeable amount dedicated to online order fulfillment. TGT, along with Walmart (NYSE:WMT) and other retail powers are coming off a strong second quarter. Now, Target stock looks like it might be worth buying ahead of what could be a big holiday shopping season.
TGT AMZN COST KSS M WMT
2018-09-14 seekingalpha - 1
REITs are unique in terms of their ability to grow moats; there are essentially two valuable levers that the company can (and should) utilize to build competitive advantage.
JCP DCT OPRF PSA.A CVS SHLD AMT EQY PSB ROST PSA EQIT WPC DRE KDNUU SBRA PSAXZ CCP VTR PPS COST O KND PLD
MEXICO CITY, Sept 14 — Walmart Inc will acquire Latin American food delivery service Cornershop for US$225 million, it said yesterday, in a move to ramp up its online grocery business in Mexico and Chile.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to COST / Costco Wholesale Corp. on message board site Silicon Investor.
as of ET